BIM23B065
Phase 2Small molecule
IpsenBIM23B065 is one of 22 small molecule programs targeting Acromegaly. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Acromegaly
#DrugCompanyPhaseTrials
1Sandostatin
Sun PharmaApproved
Lanreotide Acetate
AAlbireo, an Ipsen Company
Approved
Sandostatin LAR
NovartisApproved
Octreotide Depot
NovartisApproved
Signifor
RRECORDATI GROUP
Phase 3
Pasireotide LAR
NovartisPhase 3
Debio 025
DDebiopharm International SA
Phase 3
Palsonify
CCrinetics Pharmaceuticals Inc.
Phase 3
Clomid
FerringPhase 2
Sandostatin LAR Depot
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BIM23B065. EMBL-EBI & Wellcome Sanger Institute.
- [4]